Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3285075 | 0.85 | NPSR1 (0.44) | RAB9APOLBATMCYP1A2CYP2C9 | |
| SCHEMBL891106 | 0.83 | NPSR1 (0.54) | RAB9APOLBATMCYP1A2CYP2C9 | |
| SCHEMBL4470793 | 0.82 | CYP1A2 (0.43) | RAB9APOLBATMCYP1A2CYP2C9 | |
| SCHEMBL9748797 | 0.80 | CYP1A2 (0.41) | RAB9APOLBATMCYP1A2CYP2C9 | |
| SCHEMBL1919419 | 0.80 | CYP1A2 (0.41) | RAB9APOLBATMCYP1A2CYP2C9 | |
| SCHEMBL3156800 | 0.80 | CYP1A2 (0.54) | RAB9APOLBATMCYP1A2CYP2C9 | |
| SCHEMBL2761841 | 0.80 | CYP1A2 (0.49) | CYP1A2CYP2C9CYP2C19ALDH1A1NPSR1 | |
| SCHEMBL4205954 | 0.79 | CYP1A2 (0.76) | RAB9APOLBATMCYP1A2CYP2C9 | |
| SCHEMBL27405249 | 0.79 | BRD4 (0.68) | RAB9APOLBCYP1A2ALDH1A1NPSR1 | |
| SCHEMBL10232133 | 0.78 | LMNA (0.43) | RAB9APOLBATMCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906550-B2 | Viricide against hepatitis virus; pyrrole derivatives as, for example, 3-acetyl-4,5-dimethyl-2-pyrrole carboxylic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-15 | — | — | US | disclosed |
| US-7709503-B2 | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080125376-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-29 | — | — | US | disclosed |
| US-7365092-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1664025-B1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| US-20060223801-A1 | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
| CN-1829507-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2006-09-06 | — | — | CN | disclosed |
| EP-1664025-A1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| EP-1613620-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050080017-A1 | Inhibitors of serine proteases, particularly HVC NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2005-04-14 | — | — | US | disclosed |
| WO-2005026149-A1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2004092161-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223801-A1 | Pyrrol derivatives with antibacterial activity | PEF1, PEPD, PELP1 | RAB9A 961/4885POLB 127/4885ATM 4474/4885 |
| US-20080125376-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | RAB9A 2568/4885POLB 3080/4885ATM 3577/4885 |
| US-20050080017-A1 | Inhibitors of serine proteases, particularly HVC NS3-NS4A protease | HPN, PRSS1, SERPINB1 | RAB9A 2884/4885POLB 3674/4885ATM 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.